Rare blood clot events more com­mon among women re­ceiv­ing As­traZeneca Covid-19 vac­cine, EMA says

The EMA is stick­ing with its state­ment that As­traZeneca’s Covid-19 vac­cine is safe and ef­fec­tive, but the agency al­so dis­cussed new da­ta show­ing that younger women are more fre­quent­ly see­ing these very rare cas­es of some­times fa­tal blood clots when com­pared with the gen­er­al pop­u­la­tion, al­though more women al­so re­ceived the vac­cine than men.

EMA ex­ec­u­tive di­rec­tor Emer Cooke said Wednes­day at a press con­fer­ence that the agency’s safe­ty com­mit­tee is still re­view­ing the rare events, known as cere­bral ve­nous si­nus throm­bo­sis (CVST), which as of March 22, to­tal 62 out of 9.2 mil­lion As­traZeneca vac­ci­na­tions across the Eu­ro­pean Eco­nom­ic Area (EEA). Four­teen of those 62 cas­es were fa­tal, and 44 oc­curred in the EEA, she not­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER